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ABSTRACT
Introduction: Dapagliflozin, a sodium-glucose
co-transporter 2 inhibitor, decreases plasma
glucose levels by suppressing renal glucose
reabsorption and increasing urinary glucose
excretion. Previously published pre-clinical
data suggest that dapagliflozin lacks
carcinogenic potential. This article reviews
data on bladder cancer with dapagliflozin to
illustrate the challenges in assessing bladder
cancer in drug development programs in
patients with type 2 diabetes mellitus (T2DM).
Methods: Clinical cases of bladder cancer were
analyzed in a pooled population of [9000
patients in 21 phase 2b/3 dapagliflozin clinical
trials of up to 208 weeks’ duration.
Results: In the 21-study pool, demographic
and baseline characteristics were generally
consistent between dapagliflozin and
comparator groups. The overall incidence of
malignancies was also balanced between the
treatment groups, with an incidence rate ratio
(IRR) of 1.035 [95% confidence interval (CI):
0.724, 1.481]. Nine of 5936
dapagliflozin-treated patients and 1 of 3403
comparator-treated patients reported bladder
cancer, with an IRR of 5.168 (95% CI: 0.677,
233.55). All of these patients had clinical
attributes typical of bladder cancer in the
general population (C60-year-old males; 8 of
the 10 patients were current/former smokers).
All cases of bladder cancer were reported within
2 years of starting study treatment. There was
an absence of detailed workup of hematuria
prior to randomization, and no hematuria
workup data were collected proactively in the
dapagliflozin trials, which is typical of clinical
practice. Failure to exclude bladder cancer prior
to randomization increases the chance of
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recruiting patients with pre-existing bladder
cancer in clinical trials and may delay the final
diagnosis. Of the nine dapagliflozin-treated
patients with bladder cancer, eight had
microscopic hematuria prior to start of
treatment or within 6 months of initiating
study treatment.
Conclusion: The assessment of bladder cancer
data illustrates the challenges of characterizing
cancer risk in T2DM drug development
programs. The totality of evidence to date does
not suggest a causal relationship between
dapagliflozin and bladder cancer.
Funding: AstraZeneca.
Keywords: Bladder cancer; Dapagliflozin;
Hematuria; SGLT2 inhibitor; Type 2 diabetes
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INTRODUCTION
Epidemiologic data suggest that people with
diabetes are at a significantly higher risk of
many forms of cancer [1]. However, it is not
clear if diabetes itself is an independent risk
factor for cancer, or if the association can be
explained by common risk factors such as
obesity and a sedentary lifestyle shared
between diabetes and several forms of cancer.
Specifically, data show that type 2 diabetes
mellitus (T2DM) may be associated with an
increased risk of bladder cancer, with a
meta-analysis showing 35% increased risk in
patients with diabetes versus a healthy
population, [2, 3], although this positive
association may be limited to patients with
longstanding diabetes and/or to insulin users [4,
5]. One study reported increased odds of
bladder cancer in patients with T2DM of
C16 years’ standing versus non-diabetics [odds
ratio 3.6; 95% confidence interval (CI): 1.1,
11.2] [5].
Against this background, the influence of
glucose-lowering drugs on cancer risk is of great
interest, and several therapies have been under
scrutiny because of signals for potential
increased cancer risk. Due to the relative
infrequency of cancer events, detecting a
cancer signal in pre-marketing clinical
development programs is very difficult.
Therefore, assessment should be based on the
totality of evidence, including pre-clinical and
clinical data, individual case reports, as well as
continued monitoring for any potential signals
in post-marketing surveillance and longer-term
clinical studies.
Data suggest that long-term use of insulin
glargine ([5 years) may increase the risk of
breast cancer [6]. However, findings from the
ORIGIN trial (Outcome Reduction with Initial
Glargine Intervention; ClinicalTrials.gov
#NCT00069784) [7], which enrolled 12,537
patients and followed them for a median of
6.2 years, found no increased breast cancer risk
with insulin glargine versus standard therapy [8,
9]. Further, a potential link between
glucagon-like peptide-1 receptor agonists
(GLP-1 RAs) and pancreatic carcinoma and
thyroid cancer has also been of concern in
recent years. However, no clear conclusions
have been drawn regarding a causal
relationship with pancreatic disease
(pancreatic cancer and pancreatitis) [10–13].
With regard to thyroid cancer, clinical data
have not shown any association between GLP-1
RAs and thyroid cancer in patients with T2DM
[14].
There have also been some concerns about
the potential association between the
thiazolidinedione pioglitazone [a peroxiosome
proliferator-activated receptor (PPAR)c agonist)
and bladder cancer [15, 16], which was
evaluated in a 10-year epidemiologic study.
Although a 5-year interim analysis of this
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study showed a statistically significant increased
risk of bladder cancer among patients on
pioglitazone for C2 years [17], the 10-year final
analysis did not show any statistically
significant increases [18]. Reflecting this, the
updated American Diabetes Association/
European Association for the Study of Diabetes
position statement states that earlier concerns
about the association of pioglitazone and
bladder cancer have been dismissed by
evidence provided by recently published
clinical studies [19, 20].
More recently, sodium-glucose
co-transporter 2 (SGLT2) inhibitors have
emerged as a novel class of oral medications
for T2DM. Dapagliflozin works by suppressing
renal glucose reabsorption and increasing
urinary glucose excretion via SGLT2
inhibition, thereby leading to decreases in
plasma glucose levels [21]. Dapagliflozin is
approved for adults with T2DM in the USA as
an adjunct to diet and exercise [22], and in
Europe for use as monotherapy or add-on
combination therapy [23]. A fixed dose
combination of dapagliflozin and metformin is
also approved in the USA and Europe as an
adjunct to diet and exercise when treatment
with both dapagliflozin and metformin is
appropriate [24, 25]. Bladder cancer concerns
were raised with dapagliflozin due to the
observed numerical imbalance between
treatment groups in the new drug application
submitted to the Food and Drug Administration
in 2011; 9 out of 5478 patients on dapagliflozin
and 1 out of 3156 patients on control reported
bladder cancer in the pooled dapagliflozin
studies [26]. Bladder cancer occurrences have
not been reported in humans with other SGLT2
inhibitors; while they have been shown to
induce tumors (although not urothelial
tumors of the kidney pelvis, ureters, or
bladder) in rats [27] and male mice [28], the
associated mechanisms are not considered
relevant to humans.
This article reviews data on bladder cancer
with dapagliflozin to illustrate the
methodologic challenges in assessing cancer
risk in drug development programs in T2DM.
The article further highlights complications in
the assessment of bladder cancer in the case of




The potential for SGLT2 inhibition and
exposure to dapagliflozin to induce tumors or
enhance tumor growth have been examined in
pre-clinical studies. This includes studies of
cancers in general, as well as bladder cancer in
particular.
Pharmacologically, dapagliflozin does not
raise any concerns as SGLT2 is not expressed
in bladder tissue [29], and the action of
dapagliflozin is highly specific to SGLT2, with
no off-target effects observed across an in vitro
screen of [330 receptors, enzymes, ion
channels, and transporters [30]. The presence
of glucosuria did not enhance background
hyperplastic effects, or lead to or enhance
bladder tumors in in vivo or in vitro models.
Dapagliflozin induced extensive glucosuria in
both rodents and dogs that exceeded human
urinary glucose concentrations (166 mM) and
did not lead to bladder proliferative or tumor
development [30, 31]. Furthermore, there was
no evidence of hyperplasia or neoplasia in the
kidney or bladder of SGLT2 knockout mice with
glucosuria of *2000 mg/dL, compared with its
wild-type counterpart with no glucosuria [32].
There was also no evidence of carcinogenic
potential for dapagliflozin in toxicology studies.
A recent study showed that the exposure of
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CD-1 mice and Sprague–Dawley rats to
dapagliflozin for up to 2 years at C100-fold
human clinical exposure did not increase
tumor incidence or bladder proliferative/
preneoplastic lesions [33]. No proliferative or
hyperplastic changes were observed in dogs (a
species that has been shown to be highly
predictive of human bladder carcinogens [34])
over 1 year at [3000-fold human clinical
exposure of dapagliflozin. In summary, these





Cancer cases were analyzed in a pooled
population of[9000 patients taking part in 21
phase 2b/3 dapagliflozin clinical trials ranging
from 12 to 208 weeks’ duration (five phase 2b
studies of 12 weeks’ duration, and 16 phase 3
studies of 24–208 weeks’ duration) (see Table S1
in the Electronic Supplementary Material).
Treatment groups included dapagliflozin (2.5,
5, 10, 20, and 50 mg) versus comparator
(placebo with or without background
medications or active control including
benchmark treatments). Overall, only 59 and
56 patients received 20 and 50 mg doses of
dapagliflozin, respectively, for 12 weeks, with
the remainder receiving dapagliflozin 2.5, 5 and
10 mg.
Hematuria was measured at baseline and
during clinic visits. The frequency of patient
visits during the treatment period was different
in individual studies, varying from weekly visit
in the beginning to every 4th week in
short-term studies, and every 12th week in
long-term studies. Urine dipstick analyses were
performed at all visits, and samples with
positive dipstick underwent microscopic
urinalysis.
Events were identified according to the
Standardized MedDRA Query of ‘malignant or
unspecified tumors’.
The analysis reported in this article is based
on previously conducted studies and does not
involve any new studies of human or animal
subjects performed by any of the authors.
Statistical Analyses
Incidence rate ratio (IRR) and Kaplan–Meier
estimates of events were calculated. Due to the
small number of bladder cancer cases, analyses
of IRR were estimated using the Cox
proportional hazard ratio model stratified by
study [35].
Clinical Findings
The number of patients in the dapagliflozin
group (n = 5936) was much higher than in the
comparator group (n = 3403). Demographic
and baseline characteristics were generally
consistent between the two groups (Table 1).
Most patients were\65 years of age and were
overweight or obese; almost 90% of patients in
both groups had a body mass index (BMI)
C25 kg/m2, while approximately half of all
patients had a BMI C30 kg/m2. Mean duration
of T2DM was 7.0 and 7.6 years in the
dapagliflozin and comparator groups,
respectively, and mean baseline glycated
hemoglobin (HbA1c) values were 8.21% and
8.14%, respectively. Overall, 43.3% and 46.3%
of patients in the dapagliflozin and comparator
groups, respectively, had a history of smoking.
The pooled analysis included patients from an
add-on to pioglitazone study (n = 420) and
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Table 1 Demographic and baseline characteristics
Dapagliﬂozin (n5 5936) Comparator (n 5 3403)
Age, years
Mean ± SD 56.9 ± 10.44 58.1 ± 10.33
Age categorization, years, n (%)
\65 4512 (76.0) 2424 (71.2)
C65 and\75 1217 (20.5) 859 (25.2)
C75 207 (3.5) 120 (3.5)
Gender, n (%)
Male 3243 (54.6) 1964 (57.7)
Female 2693 (45.4) 1439 (42.3)
Race, n (%)
White 4505 (75.9) 2644 (77.7)
Black/African American 208 (3.5) 125 (3.7)
Asian 1050 (17.7) 513 (15.1)
Other 173 (2.9) 121 (3.6)
BMI, kg/m2, n (%)
C25 5214 (87.8) 2998 (88.1)
C30 3368 (56.7) 1949 (57.3)
Smoking history, n (%)
Current 998 (16.8) 562 (16.5)
Former 1572 (26.5) 1014 (29.8)
Duration of T2DM, years
Mean ± SD 6.95 ± 7.49 7.59 ± 7.68
Median (range) 4.50 (0.0, 54.4) 5.20 (0.0, 48.0)
HbA1c, % (mmol/mol)
Mean ± SD 8.21 ± 1.03 (66 ± 11.3) 8.14 ± 1.02 (65 ± 11.1)
FPG, mg/dL (mmol/L)
Mean ± SD 167.21 ± 48.78 (9.28 ± 2.71) 165.27 ± 46.48 (9.17 ± 2.58)
Seated systolic blood pressure. mmHg
Mean ± SD 130.4 ± 15.66 131.1 ± 14.88
Seated diastolic blood pressure, mmHg
Mean ± SD 78.8 ± 9.10 78.8 ± 8.94
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from four studies with background insulin and/
or oral antidiabetic drugs (n = 3017).
Malignant or Unspecified Tumors
The overall incidence rate of malignancies was
balanced between dapagliflozin and comparator
groups; 89/5936 (1.5%) patients treated with
dapagliflozin and 51/3403 (1.5%) patients
treated with comparator had malignant or
unspecified tumors. The IRR for overall
malignant and unspecified tumors was 1.035
(95% CI: 0.724, 1.481; p = 0.849). The
time-to-first-event analyses of malignant and
unspecified tumors (Kaplan–Meier estimates)
were also similar between patients treated with
dapagliflozin and comparator (Table 2).
When different cancer types were analyzed,
the incidence rates were numerically lower in the
dapagliflozin group versus comparator for some
organcategories (e.g., renal, female reproductive),
and greater in the dapagliflozin group versus
comparator for other organ categories (e.g.,
bladder, breast) (Fig. 1). There was no obvious
pattern to the distribution of various tumor types,
with no clear pathophysiologic link between the
tumor types favoring dapagliflozin or
comparator. The CIs for the incidence rate for all
specific tumor types included unity, indicating
that there was no statistically significant
difference between treatment groups. The
majority of patients with cancer were diagnosed
within 1 year of initiating study drug treatment
(72% and 63% in the dapagliflozin and
comparator groups, respectively).
Bladder Cancer
Nine of 5936 dapagliflozin-treated patients
(0.15%) and 1 of 3403 comparator-treated
patients (0.03%) reported bladder cancer
events (Table 3). This corresponds to an
unstratified incidence rate of 135 events per
100,000 patient-years for dapagliflozin-treated
patients and 26 events per 100,000 patient-years
for comparator-treated patients, with an IRR of
5.168 (95% CI: 0.677, 233.55) (Table 4).
All patients reporting bladder cancer were
male, most were C60 years old, and had clinical
attributes typical of bladder cancer in the
general population; the pattern of urothelial
cell carcinomas detected during the study
period was typical of the general population
[36], with approximately 50% being low-grade
non-invasive cancer at first diagnosis.
Furthermore, 8/10 patients with events of
Table 1 continued
Dapagliﬂozin (n5 5936) Comparator (n 5 3403)
GFR, mL/min/1.73 m2, n (%)
\30 9 (0.2) 6 (0.2)
C30 to\60 668 (11.3) 387 (11.4)
C60 to\90 3113 (52.4) 1793 (52.7)
C90 2146 (36.2) 1216 (35.7)
Includes all treated patients from 21 phase 2b/3 dapagliﬂozin clinical trials ranging from 12 to 208 weeks’ duration (ﬁve
phase 2b studies of 12 weeks’ duration and 16 phase 3 studies with 24–208 weeks’ duration)
BMI body mass index, FPG fasting plasma glucose, GFR glomerular ﬁltration rate, HbA1c hemoglobin A1c, SD standard
deviation, T2DM type 2 diabetes mellitus
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bladder cancer were current or former smokers.
These findings are consistent with data from
previous studies reporting bladder cancer
predominance in smokers [37, 38]. It should
be noted that history of smoking in patients
who reported bladder cancer was higher than in
the overall study population of male
dapagliflozin- and comparator-treated patients
(58.5% and 61.1%, respectively, were current or
former smokers).
Table 2 Cumulative proportion of patients with malignant and unspeciﬁed tumors (Kaplan–Meier analysis)
Week Dapagliﬂozin (n5 5936) Comparator (n 5 3403)
n N# Proportion, % (95% CI) n N# Proportion, % (95% CI)
\18 24 5347 0.42 (0.25–0.59) 11 3070 0.34 (0.14–0.54)
\26 31 4846 0.57 (0.37–0.77) 15 2771 0.48 (0.24–0.73)
\52 64 3245 1.50 (1.13–1.88) 31 1911 1.25 (0.80–1.70)
\104 85 1552 2.69 (2.06–3.32) 45 774 2.69 (1.81–3.57)
\208 89 156 3.93 (2.27–5.59) 50 135 5.76 (2.97–8.54)
\216 89 3 3.93 51 2 6.46
Including data after rescue
n Number of patients with an event of malignant cancer, N number of treated patients, N# number of patients at risk at the
beginning of the period, CI conﬁdence interval
Fig. 1 Incident rate ratio of malignant and unspeciﬁed
tumors by organ category from the dapagliﬂozin clinical
trials. N is the number of treated patients. Only trials with
at least one selected event contributed to the analysis.
Conﬁdence intervals are based on an exact method.
Includes serious and non-serious adverse events on or after
the ﬁrst date/time of double-blind treatment and on or
prior to the last day of short-term plus long-term treatment
?30 days (or up to follow-up visit whichever was ﬁrst) or
?4 days
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The hypothesis that symptoms related to
increased urinary volume and increased events
of urinary tract infections (UTIs) with
dapagliflozin treatment led to increased
bladder cancer detection bias has not been
fully tested. In clinical studies of dapagliflozin,
three patients had urinary events prior to
bladder cancer diagnosis: one
dapagliflozin-treated patient had a UTI on day
84 of the study (bladder cancer was detected on
day 144), the second dapagliflozin-treated
patient had an adverse event (AE) of benign
prostatic hypertrophy on day 727 (the same day
as cystoscopy workup for benign prostatic
hypertrophy; bladder cancer was detected as
an incidental finding), and the third
comparator-treated patient had cystitis on day
32 (bladder cancer was detected on day 136).
Eight of the nine bladder cancer patients
who received dapagliflozin were treated with
background glucose-lowering medications:
insulin (n = 3), metformin (n = 2), metformin
and sulfonylurea (n = 2), and pioglitazone
(n = 1). The patient in the comparator group
who reported bladder cancer received insulin
and metformin background therapy (Table 3).
All ten cases of bladder cancer were reported
within 2 years of starting study treatment
(range 43–727 days) (Fig. 2). The bladder
cancer events were diagnosed in the
dapagliflozin-treated patients in \6 months
(n = 4), 6 to \12 months (n = 1), 12 to
\18 months (n = 2), and 18 to \24 months
(n = 2) of starting the study drug, which is a
relatively short amount of time when
considering the latency period for human
bladder carcinogenesis [39, 40].
Hematuria and Bladder Cancer
Hematuria, microscopic or macroscopic, is the
most common symptom of bladder cancer. In
addition to being a manifestation of bladder
cancer, hematuria can also be a sign of
carcinoma in situ and may be associated
with bladder cancer detected up to 6 years
later [41].
Of the nine dapagliflozin-treated patients
with bladder cancer, eight had microscopic
hematuria prior to start of treatment or within
6 months of initiating study drug treatment
(Fig. 3) and one reported hematuria 6 months
after initiating study treatment. The patient
with bladder cancer in the comparator-treated
group had evidence of hematuria prior to start
of treatment. It should be noted that in the
Table 4 Adverse events of bladder cancer, including data after rescue
Dapagliﬂozin (n5 5936) Comparator (n5 3403)
Exposure, patient-years 6650 3864
Patients with events, n (%) 9 (0.15) 1 (0.03)
Incident rate per 100 patient-years 0.135 0.026
Incident rate ratio vs comparator (95% CI)a 5.168 (0.677, 233.55) –
a One additional case of bladder cancer in a patient treated with dapagliﬂozin 10 mg has been reported since database lock.
The subject is a female,\60 years of age and a current smoker (20 cigarettes/day for 40 years). Bladder cancer was diagnosed
within 3.5 months of starting treatment with dapagliﬂozin suggesting that the cancer was pre-existent. The incidence rate
ratio in the dapagliﬂozin total group versus comparator including this additional event is 6.111 (95% CI: 0.827, 272.02)
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Fig. 3 Relationship between ﬁrst hematuria event after randomization and time to ﬁrst bladder cancer event
Fig. 2 Kaplan–Meier plot of time to ﬁrst event of bladder
cancer. Includes data after rescue. Week is not scheduled
week visit, but actual days from the ﬁrst dose of
double-blind study medication divided by 7. The number
of patients at risk is the number of patients at risk in the
beginning of the period
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overall pool of[9000 patients, the prevalence
of hematuria at baseline was similar in patients
receiving dapagliflozin and comparator [8.5% of
patients on dapagliflozin (3.7% of men and
14.2% of women) versus 8.1% on comparator
(4.2% of men and 13.4% of women)].
DISCUSSION
The assessment of bladder cancer data from the
dapagliflozin drug development program
illustrates the challenge of characterizing
cancer risk in T2DM, particularly individual
cancer types where the number of cases is low
and statistical conclusion is not possible.
Pre-clinical studies indicated that dapagliflozin
is not carcinogenic. In addition to rigorously
demonstrating that dapagliflozin is not an
initiator of tumor development, neither the
drug, its primary metabolite, nor drug-induced
glucosuria have been found to enhance the
growth of human bladder cancer cells in vitro or
in a mouse xenograft model [30, 33]. Further,
exposure to dapagliflozin in the presence of
extensive glucosuria did not lead to the
conversion of hyperplastic cells to bladder
tumors. Therefore, the possibility of tumor
cells being more susceptible to the potential
growth effects of glucosuria seems unlikely.
These findings are in contrast with studies of
known carcinogenic agents such as estrogen, for
which several mechanisms are postulated and
where there is a clear link to breast cancer in
humans [42]. Pre-clinical data have shown an
association between pioglitazone exposure and
bladder tumors in male rats; tumor formation
was considered secondary to the formation of
urinary solids with subsequent irritation and
hyperplasia [43]. A similar rat-specific mode of
action for urinary bladder tumors was
demonstrated by the PPARc/a agonist,
muraglitazar [44, 45]. Further, as described
earlier, other less selective SGLT2 inhibitors
have been shown to induce tumors (although
not urothelial tumors of the kidney pelvis,
ureters, or bladder) in animal studies [27, 28],
but the associated mechanisms are considered
irrelevant to humans. Such findings therefore
bring SGLT2 inhibitors under increased scrutiny
for their carcinogenic potential.
This post hoc pooled analysis of
dapagliflozin clinical trials showed no obvious
pattern in the distribution of various tumors,
with no statistically significant differences
between treatment groups for any tumor
types. The number of bladder cancer cases was
small, but numerical imbalances were noted
between treatment groups [46]. It should be
noted that the characteristics of patients
reporting urothelial cell carcinomas during the
study period were C60 years old, male, and
most were current or former smokers and
typical of the general population. Although it
does not explain the greater number of cancer
cases in patients treated with dapagliflozin
versus comparator, these data highlight that
some well-established and potent risk factors of
bladder cancer in patients with T2DM were
present, which cannot be ignored.
The assessment of incidence rates in a
clinical trial versus real-world population has
its own challenges. The dapagliflozin trials were
not large enough and were not designed to
assess the risk of bladder cancer (as noted by the
wide 95% CIs), and it is questionable whether
data reported in the dapagliflozin trials can be
extrapolated to a larger, ‘‘real life’’ population of
patients with bladder cancer. Furthermore, the
incidence rates for bladder cancer in the general
population vary among different countries and
between databases—this could potentially be
related to an absence of routine screening for
bladder cancer detection.
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The assessment of bladder cancer with
dapagliflozin may also potentially be
confounded because of the drug-induced
diuresis and symptomatology associated with
genitourinary infections. This could have
possibly prompted more rigorous
investigations in the dapagliflozin treatment
groups, leading to detection of pre-existing
bladder cancers. However, this hypothesis
cannot be confirmed because of the absence of
systematic collection of data for medical
procedures related to cancer diagnosis in these
trials.
Previous studies have shown an association
between recurrent UTIs and bladder cancer [47,
48], and therefore one important question was
whether the bladder cancer cases with
dapagliflozin were related to increased rates of
UTIs. However, of the ten patients reporting
bladder cancer in the dapagliflozin clinical
development program, seven were not
preceded by urinary events. Furthermore,
other SGLT2 inhibitors, which are associated
with very similar patterns of infection, were not
associated with bladder cancer imbalances in
clinical trials. Hence, these observations do not
support a causal relationship between UTIs in
dapagliflozin-treated patients and bladder
cancer.
Bladder carcinomas usually have a latency
period of several years [34]. In one study,
cyclophosphamide, a well-described bladder
carcinogen, was administered to patients with
Wegener’s syndrome with a median drug
exposure of 2.7 years. The estimated incidence
of bladder cancer after the first exposure to
cyclophosphamide was 5% at 10 years [49]. In
contrast, the time from initiation of
dapagliflozin to bladder cancer development
was much shorter, making it unlikely that the
exposure to dapagliflozin in studies to date
would have been long enough to produce a
quantifiable effect on bladder tumor
development or growth.
Unlike in daily practice, urinalysis is often
conducted in clinical trials, making the
detection of hematuria more likely. However,
there was an absence of detailed workup of
hematuria prior to randomization in the
dapagliflozin trials, which is typical of clinical
practice [50]. No specific direction was provided
and no hematuria workup data were collected
proactively until later studies, where local
guidance was followed. The management and
follow-up of hematuria are often ambiguous
due to lack of clarity surrounding definitions,
diagnosis, and referral criteria. Studies have
suggested that most patients with hematuria
are not appropriately referred to urologists for
evaluation [51–53]. Failure to exclude bladder
cancer prior to randomization increases the
likelihood of recruiting patients with
pre-existing bladder cancer in clinical trials or
may delay the final diagnosis to after the study
initiation. In the present analysis, all except one
patient had hematuria prior to the start of
treatment or within 6 months of initiating the
study drug, and it took several additional weeks
or months to establish the final diagnosis of
bladder cancer. Such findings highlight an
unmet need for improved guidance regarding
a complete workup of hematuria or any other
potential indicators of pre-existing cancers for
clinical trials conducted in patients with T2DM.
It is important to note that in clinical practice,
the use of dapagliflozin should not be precluded
in patients presenting with hematuria, and
neither is it necessary to routinely screen for
hematuria before or during dapagliflozin
treatment.
In summary, the totality of evidence to date
does not suggest a causal relationship between
dapagliflozin and bladder cancer, and the
observed effect in clinical trials may be a
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chance finding. However, given the observed
imbalances, any firm conclusion cannot be
made without additional clinical data, and as
such accruing bladder cancer events are being
carefully investigated in ongoing trials of
dapagliflozin.
CONCLUSION
The case of dapagliflozin illustrates the
challenges of interpreting bladder cancer
events with a drug associated with urinary
symptoms and in a disease where the
background incidence of bladder cancer is
elevated. An important learning from the
dapagliflozin experience is the need for
improved and comprehensive follow-up of
hematuria in clinical trials at baseline and
throughout the study period, and in real-world
populations.
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